These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 37079778)
21. β-Amyloid, Tau, Neurodegeneration Classification and Eligibility for Anti-amyloid Treatment in a Memory Clinic Population. Rosenberg A; Öhlund-Wistbacka U; Hall A; Bonnard A; Hagman G; Rydén M; Thunborg C; Wiggenraad F; Sandebring-Matton A; Solomon A; Kivipelto M Neurology; 2022 Nov; 99(19):e2102-e2113. PubMed ID: 36130840 [TBL] [Abstract][Full Text] [Related]
22. A two-step immunoassay for the simultaneous assessment of Aβ38, Aβ40 and Aβ42 in human blood plasma supports the Aβ42/Aβ40 ratio as a promising biomarker candidate of Alzheimer's disease. Shahpasand-Kroner H; Klafki HW; Bauer C; Schuchhardt J; Hüttenrauch M; Stazi M; Bouter C; Wirths O; Vogelgsang J; Wiltfang J Alzheimers Res Ther; 2018 Dec; 10(1):121. PubMed ID: 30526652 [TBL] [Abstract][Full Text] [Related]
23. Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative. Veitch DP; Weiner MW; Aisen PS; Beckett LA; Cairns NJ; Green RC; Harvey D; Jack CR; Jagust W; Morris JC; Petersen RC; Saykin AJ; Shaw LM; Toga AW; Trojanowski JQ; Alzheimers Dement; 2019 Jan; 15(1):106-152. PubMed ID: 30321505 [TBL] [Abstract][Full Text] [Related]
24. Plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross-sectional and longitudinal study in the AIBL cohort. Chatterjee P; Pedrini S; Doecke JD; Thota R; Villemagne VL; Doré V; Singh AK; Wang P; Rainey-Smith S; Fowler C; Taddei K; Sohrabi HR; Molloy MP; Ames D; Maruff P; Rowe CC; Masters CL; Martins RN; Alzheimers Dement; 2023 Apr; 19(4):1117-1134. PubMed ID: 36574591 [TBL] [Abstract][Full Text] [Related]
25. Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Aβ42/Aβ40 and p-tau. Janelidze S; Palmqvist S; Leuzy A; Stomrud E; Verberk IMW; Zetterberg H; Ashton NJ; Pesini P; Sarasa L; Allué JA; Teunissen CE; Dage JL; Blennow K; Mattsson-Carlgren N; Hansson O Alzheimers Dement; 2022 Feb; 18(2):283-293. PubMed ID: 34151519 [TBL] [Abstract][Full Text] [Related]
26. Additional use of Aβ₄₂/Aβ₄₀ ratio with cerebrospinal fluid biomarkers P-tau and Aβ₄₂ increases the level of evidence of Alzheimer's disease pathophysiological process in routine practice. Sauvée M; DidierLaurent G; Latarche C; Escanyé MC; Olivier JL; Malaplate-Armand C J Alzheimers Dis; 2014; 41(2):377-86. PubMed ID: 24614902 [TBL] [Abstract][Full Text] [Related]
27. Impact of pre-analytical sample handling factors on plasma biomarkers of Alzheimer's disease. Kurz C; Stöckl L; Schrurs I; Suridjan I; Gürsel SÜ; Bittner T; Jethwa A; Perneczky R J Neurochem; 2023 Apr; 165(1):95-105. PubMed ID: 36625424 [TBL] [Abstract][Full Text] [Related]
28. Plasma tau, neurofilament light chain and amyloid-β levels and risk of dementia; a population-based cohort study. de Wolf F; Ghanbari M; Licher S; McRae-McKee K; Gras L; Weverling GJ; Wermeling P; Sedaghat S; Ikram MK; Waziry R; Koudstaal W; Klap J; Kostense S; Hofman A; Anderson R; Goudsmit J; Ikram MA Brain; 2020 Apr; 143(4):1220-1232. PubMed ID: 32206776 [TBL] [Abstract][Full Text] [Related]
29. Plasma p-tau181, p-tau217, and other blood-based Alzheimer's disease biomarkers in a multi-ethnic, community study. Brickman AM; Manly JJ; Honig LS; Sanchez D; Reyes-Dumeyer D; Lantigua RA; Lao PJ; Stern Y; Vonsattel JP; Teich AF; Airey DC; Proctor NK; Dage JL; Mayeux R Alzheimers Dement; 2021 Aug; 17(8):1353-1364. PubMed ID: 33580742 [TBL] [Abstract][Full Text] [Related]
30. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Jack CR; Bennett DA; Blennow K; Carrillo MC; Dunn B; Haeberlein SB; Holtzman DM; Jagust W; Jessen F; Karlawish J; Liu E; Molinuevo JL; Montine T; Phelps C; Rankin KP; Rowe CC; Scheltens P; Siemers E; Snyder HM; Sperling R; Alzheimers Dement; 2018 Apr; 14(4):535-562. PubMed ID: 29653606 [TBL] [Abstract][Full Text] [Related]
31. Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's disease. Gangishetti U; Christina Howell J; Perrin RJ; Louneva N; Watts KD; Kollhoff A; Grossman M; Wolk DA; Shaw LM; Morris JC; Trojanowski JQ; Fagan AM; Arnold SE; Hu WT Alzheimers Res Ther; 2018 Sep; 10(1):98. PubMed ID: 30253800 [TBL] [Abstract][Full Text] [Related]